Erythropoiesis‐Stimulating Agent Use for Anemia Induced by Interferon‐Ribavirin Treatment in Patients with Hepatitis C Virus Infection Is Not Associated with Increased Rates of Cardiovascular Disease, Thrombosis, Malignancy, or Death | Zendy

Cecilia T. Costiniuk | Zendy; Fernando Camacho | Zendy; Curtis Cooper | Zendy

Open Access

Erythropoiesis‐Stimulating Agent Use for Anemia Induced by Interferon‐Ribavirin Treatment in Patients with Hepatitis C Virus Infection Is Not Associated with Increased Rates of Cardiovascular Disease, Thrombosis, Malignancy, or Death

Author(s) -

Cecilia T. Costiniuk,

Fernando Camacho,

Curtis Cooper

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/589243

Subject(s) - medicine , ribavirin , hepatitis c virus , context (archaeology) , anemia , hepatitis c , complication , thrombosis , erythropoiesis , malignancy , immunology , gastroenterology , virus , paleontology , biology

Anemia is a complication of therapy for hepatitis C virus (HCV) infection, necessitating dose reductions or therapy abandonment. Administration of an erythropoiesis-stimulating agent (ESA) is a common strategy to manage this complication. Clinical data in other patient populations demonstrate increased rates of cardiovascular events, thrombosis, malignancy, and death among ESA recipients. Event rates in the context of HCV treatment are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research